Placebo News and Research

RSS

Intravenous cangrelor provides rapid platelet inhibition in cardiogenic shock

Compared with crushed ticagrelor, intravenous cangrelor provided immediate, effective platelet inhibition, with no increase in major bleeding and lower mortality rates in patients with acute myocardial infarction and cardiogenic shock, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

3 Sep 2025

Beetroot juice lowers blood pressure in older adults by reshaping oral bacteria

Dietary nitrate from beetroot juice lowered blood pressure in older adults but not in younger participants in a double-blind crossover trial. The effect was linked to oral microbiome changes, including reduced Prevotella and higher plasma nitrite, without improvements in endothelial function

2 Sep 2025

How raspberry leaf tea reduces insulin surges from table sugar

Trial shows that raspberry leaf tea blunts sucrose-induced glucose and insulin surges, offering a natural strategy for moderating blood sugar without the side effects of pharmaceutical enzyme inhibitors.

2 Sep 2025

Azelastine nasal spray significantly reduces SARS-CoV-2 infections in clinical trial

The trial, led by Professor Robert Bals, Director of the Department of Internal Medicine V at Saarland University Medical Center and Professor of Internal Medicine at Saarland University, divided the 450 participants into two groups.

2 Sep 2025

Gait retraining reduces pain and slows knee damage in osteoarthritis

Nearly a quarter of people over the age of 40 experience painful osteoarthritis, making it a leading cause of disability in adults.

1 Sep 2025

In-hospital start of dapagliflozin shows no significant short-term benefit in heart failure patients

In-hospital initiation of dapagliflozin did not significantly reduce the short-term risk of cardiovascular death or worsening heart failure (HF) in patients admitted for HF, although positive effects were seen when combining trial data, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Aficamten outperforms beta-blockers in treating patients with obstructive hypertrophic cardiomyopathy

Aficamten treatment was associated with significant improvements in exercise capacity and symptoms compared with metoprolol in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Baxdrostat offers hope for millions with difficult-to-control high blood pressure

A new treatment has been shown to significantly lower blood pressure in people whose levels stay dangerously high, despite taking several existing medicines, according to the results of a Phase III clinical trial led by a UCL Professor.

1 Sep 2025

Adding aspirin raises cardiovascular events in high-risk CCS patients on anticoagulants

Adding aspirin increased the risk of cardiovascular events, death and major bleeding in high-risk patients with chronic coronary syndrome (CCS) who had prior stenting and were receiving long-term chronic oral anticoagulation (OAC), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Triglyceride levels substantially reduced with olezarsen compared to placebo

Olezarsen decreased levels of triglycerides compared with placebo in patients with moderate hypertriglyceridemia and elevated cardiovascular risk, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Ivabradine fails to prevent myocardial injury after noncardiac surgery in large clinical trial

Ivabradine did not reduce the occurrence of myocardial injury after noncardiac surgery (MINS), according to late-breaking research presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Baxdrostat demonstrates strong blood pressure control with favorable safety profile in phase III trial

Baxdrostat 1 mg or 2 mg once daily led to statistically significant reductions in blood pressure compared with placebo at 12 weeks in patients with uncontrolled or treatment-resistant hypertension, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Phase II trial finds zilebesiran lowers systolic blood pressure in patients with uncontrolled hypertension

Among individuals with cardiovascular disease or high cardiovascular risk and uncontrolled hypertension on multiple anti-hypertensive agents, a single subcutaneous dose of zilebesiran 300 mg led to a 5-mmHg reduction in systolic blood pressure at Month 3 compared with placebo, a difference that did not reach statistical significance.

1 Sep 2025

Trial shows no meaningful gains with mavacamten in nonobstructive hypertrophic cardiomyopathy

Mavacamten treatment at 48 weeks was not associated with significant improvements in patient-reported health status or peak oxygen consumption compared with placebo in patients with symptomatic nonobstructive hypertrophic cardiomyopathy, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Vericiguat reduces mortality and hospitalizations in a broad range of patients with HFrEF

Vericiguat reduced the risk of cardiovascular mortality, heart failure (HF) hospitalizations and all-cause mortality across a broad range of patients with HF and reduced ejection fraction (HFrEF), according to a pooled analysis presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors

Apixaban 2.5 mg twice daily significantly reduced symptomatic venous thromboembolism (VTE) recurrence, with a low risk of major bleeding, in patients with provoked VTE and enduring risk factors, according to late-breaking research presented in a Hot Line session today at ESC Congress 2025 and simultaneously published in New England Journal of Medicine.

1 Sep 2025

Inclisiran helps more high-risk patients reach LDL cholesterol goals compared to standard therapy

More patients with hypercholesterolemia at high/very high risk of cardiovascular (CV) events achieved low-density lipoprotein cholesterol (LDL-C) goals with inclisiran compared with placebo, when given on top of individually optimized lipid-lowering therapy, according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

New trial shows benefit of digitoxin in patients with severe heart failure symptoms

Digitoxin reduced the risk of a composite of all-cause death and hospitalization for worsening heart failure (HF) among patients with advanced HF and a reduced ejection fraction (HFrEF), according to a late-breaking trial presented in a Hot Line session today at ESC Congress 2025.

1 Sep 2025

Lubiprostone shows promise in slowing kidney disease progression

Chronic kidney disease (CKD) is a major health issue worldwide. Many patients end up requiring regular dialysis to avoid kidney failure and stay alive.

1 Sep 2025

Babies fed blueberries show fewer allergy symptoms and boosted immune balance

Daily blueberry powder given to infants during complementary feeding modestly influenced allergic symptom resolution and shaped immune biomarker–microbiota associations. Findings suggest early diet may play a role in immune development, though results are preliminary and exploratory.

31 Aug 2025

Placebo News and Research

Intravenous cangrelor provides rapid platelet inhibition in cardiogenic shock

Beetroot juice lowers blood pressure in older adults by reshaping oral bacteria

How raspberry leaf tea reduces insulin surges from table sugar

Azelastine nasal spray significantly reduces SARS-CoV-2 infections in clinical trial

Gait retraining reduces pain and slows knee damage in osteoarthritis

In-hospital start of dapagliflozin shows no significant short-term benefit in heart failure patients

Aficamten outperforms beta-blockers in treating patients with obstructive hypertrophic cardiomyopathy

Baxdrostat offers hope for millions with difficult-to-control high blood pressure

Adding aspirin raises cardiovascular events in high-risk CCS patients on anticoagulants

Triglyceride levels substantially reduced with olezarsen compared to placebo

Ivabradine fails to prevent myocardial injury after noncardiac surgery in large clinical trial

Baxdrostat demonstrates strong blood pressure control with favorable safety profile in phase III trial

Phase II trial finds zilebesiran lowers systolic blood pressure in patients with uncontrolled hypertension

Trial shows no meaningful gains with mavacamten in nonobstructive hypertrophic cardiomyopathy

Vericiguat reduces mortality and hospitalizations in a broad range of patients with HFrEF

Extended apixaban therapy lowers recurrent VTE in patients with provoked events and enduring risk factors

Inclisiran helps more high-risk patients reach LDL cholesterol goals compared to standard therapy

New trial shows benefit of digitoxin in patients with severe heart failure symptoms

Lubiprostone shows promise in slowing kidney disease progression

Babies fed blueberries show fewer allergy symptoms and boosted immune balance

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News